原发性胆汁性胆管炎的治疗持续性、碱性磷酸酶正常化与临床结局
基于美国索赔与实验室数据的回顾性研究纳入20,139例接受熊去氧胆酸、奥贝胆酸或联合治疗的PBC成人,一年持续率约50%。瘙痒、乏力、腹痛、黑人种族、西班牙裔、医疗补助、基线肝硬化、门脉高压、SLE及尿路感染为停药预测因素;UDCA停药与ALP正常化几率降低相关,ALP正常化与死亡及临床结局风险降低相关。
要点
- PBC治疗一年持续率仅约50%,停药受多种临床与社会因素影响。
- UDCA停药与ALP正常化几率降低相关,持续治疗对生化应答重要。
- ALP正常化与死亡及临床结局风险降低相关,支持达标管理。
核心结论
- 治疗持续性对PBC至关重要,与ALP正常化及临床结局显著改善相关。
- 需要新策略和疗法以提高PBC患者的治疗持续性并改善临床获益。
研究设计与样本
- 回顾性研究,使用Komodo美国索赔与实验室数据(2018年9月至2023年9月)。
- 纳入20,139例接受UDCA(n=17,006)、OCA(n=1,709)或UDCA/OCA联合(n=1,424)治疗的PBC成人。
- 持续治疗定义为治疗间隙≤60天的连续治疗。
- 采用Cox模型评估停药预测因素及ALP正常化与临床结局, logistic模型分析停药与ALP正常化的关联。
主要发现
- UDCA、OCA及联合治疗队列的一年持续率分别为50%、51%和49%。
- 停药显著预测因素包括瘙痒(HR=1.09)、乏力(HR=1.09)、腹痛(HR=1.08)、黑人种族(HR=1.36)、西班牙裔(HR=1.11)、医疗补助(HR=1.13)、基线肝硬化(HR=1.08)、门脉高压(HR=1.11)、SLE(HR=1.13)(均p<0.01)及尿路感染(HR=1.06,p=0.017)。
- 基线ALP≥1.67倍正常上限的626例患者中,UDCA、OCA及联合队列分别在6-24个月内ALP正常化的比例为33%、17%和11%(OCA及联合 vs UDCA队列的p值分别为0.005和p<0.001)。
- UDCA停药与ALP正常化几率降低相关。
- ALP正常化与死亡及临床结局风险降低相关。
临床怎么用
- 应关注PBC患者治疗持续性,识别瘙痒、乏力、腹痛及社会人口学等停药风险因素。
- 持续UDCA治疗可能有助于ALP正常化,进而改善临床结局。
局限性
- 回顾性研究设计,基于美国索赔与实验室数据,可能存在混杂与信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world evidence on treatment persistence and its association with alkaline phosphatase (ALP) and clinical outcomes in primary biliary cholangitis (PBC) is limited. METHODS: We conducted a retrospective study using Komodo's US claims and laboratory data (09/2018-09/2023) of adults with PBC treated with ursodeoxycholic acid (UDCA), obeticholic acid (OCA), or concurrent UDCA/OCA. Persistence was defined as continuous treatment with ≤ 60-day gaps. Cox models evaluated predictors of discontinuation, logistic models examined associations between discontinuation and normal ALP, and Cox models assessed normal ALP and clinical outcomes. RESULTS: Among 20,139 individuals starting UDCA (n = 17,006), OCA (n = 1,709), or concurrent UDCA/OCA (n = 1,424), one-year persistence was 50%, 51%, and 49%, respectively. Significant predictors of discontinuation included pruritus (hazard ratio [HR] = 1.09), fatigue (HR = 1.09), abdominal pain (HR = 1.08), African American race (HR = 1.36), Hispanic ethnicity (HR = 1.11), Medicaid coverage (HR = 1.13), baseline cirrhosis (HR = 1.08), portal hypertension (HR = 1.11), systemic lupus erythematosus (HR = 1.13) (all p < 0.01), and urinary infection (HR = 1.06, p = 0.017). Of 626 patients with baseline ALP levels ≥ 1.67 x upper limit of normal, 33%, 17%, and 11% in the UDCA, OCA, and concurrent UDCA/OCA cohorts, respectively, had normal ALP within 6-24 months (p = 0.005 and p < 0.001 for OCA and concurrent vs. the UDCA cohort, respectively). UDCA discontinuation was associated with lower odds of having normal ALP. Normal ALP was associated with a reduced risk for mortality and clinical outcomes. CONCLUSIONS: Treatment persistence is crucial in PBC as it is associated with normal ALP and significant improvement in clinical outcomes. Novel strategies and therapies are needed to enhance persistence and improve clinical benefits among individuals with PBC.
引用
- Kowdley KV, Ieyoub J, Pan Y, et al. Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis. Aliment Pharmacol Ther. 2025. PMID: 41163430. doi:10.1111/apt.70391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。